Search the Newsreel

ACRES Commercial Realty Extends JPMorgan Funding Facility

Form 4 Acrivon Therapeutics Inc For: 24 July By Investing.com

This article reports on a Form 4 filing for Acrivon Therapeutics Inc. (ACRV) on July 24th. The filing indicates insider transaction activity for the company. The stock symbol ACRV is noted to have decreased by 4.19%.

ACRES Commercial Realty Corp. Revenue Breakdown – NYSE:ACR

ACRES Commercial Realty Corp. (NYSE: ACR) reported total revenue of $79.90 million USD last year. The Commercial Real Estate Lending segment was the top-performing segment, contributing $79.95 million USD, primarily generated in the United States. This represents a slight decrease from the previous year's …

TradingKey

This page provides an income statement for MacroGenics Inc (MGNX), detailing its quarterly and annual financial performance. It includes metrics like total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The data allows investors to analyze the company's operational …

Form 4 Acres Commercial Realty Corp For: 24 July By Investing.com

Insider tax-withholding share sale at Acrivon Therapeutics (NASDAQ: ACRV)

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, sold 573 shares of common stock at $1.76 per share on July 21, 2026. This sale was automatically executed to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units. After this transaction, Miller still …

MacroGenics Inc (MGNX) Institutional Confidence

MacroGenics Inc (MGNX) currently holds an institutional shareholding score of 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 68.70%, marking a 14.58% increase quarter-over-quarter. James Simons is the largest institutional shareholder.

MacroGenics slips on trial data for lead asset (MGNX:NASDAQ)

MacroGenics (MGNX) shares fell by nearly 6% following the release of updated results from an ongoing Phase 1 trial for its lead asset, MGC026. The drug, an antibody-based therapy, is being developed to target solid tumors. The trial data involved 74 patients.

Acrivon Therapeutics CLO Mary Miller sells $1,008 in company stock

Mary Miller, Chief Legal Officer at Acrivon Therapeutics Inc., sold 573 shares of company stock for $1,008 to cover tax withholdings. Following the sale, Miller still holds 82,194 shares, while the stock has experienced significant volatility and is down approximately 31% year-to-date. In related …

ACRES Commercial Realty (NYSE: ACR) funds sell 9,233 Series D preferred shares

Acrux Limited Releases 1.1 Million Ordinary Shares Following Vesting of Employee Performance Rights

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MacroGenics, Inc. announced a clinical update on its ongoing Phase 1 study for MGC026, a B7-H3-directed antibody-drug conjugate (ADC), for advanced solid tumors. Interim results, showing the achievement of a pre-specified response threshold in squamous cell carcinoma of the head and neck, will be …

BMA|Banco Macro SA|Price:89.110|Chg%:-2.350

Banco Macro SA (BMA) is trading at 89.110 USD, down 2.56%. The company has strong fundamentals and high growth potential, with a "Buy" rating from analysts and a target price of 117.00. Key figures show a market cap of 6.01B, a P/E TTM of …

Banco Macro SA (BMA) Stock Down 6.2% but Still Overvalued -- GF Score: 67/100

Banco Macro SA (BMA) shares dropped 6.2% to $91.63, yet GuruFocus assesses the stock as "Significantly Overvalued" with a GF Value™ of $31.73, indicating a substantial discrepancy from its intrinsic value. While the stock shows strong momentum (10/10), its valuation (1/10) and financial strength …

MGNX stock holds focus as MacroGenics plans and pipeline metrics matter

MacroGenics (MGNX) is a small-cap biotech company whose stock performance is heavily influenced by pipeline execution, balance sheet health, and financial metrics like revenue and cash use. Investors should focus on the company's reported numbers, program milestones, and clinical data readouts rather than broad …

BMA6137828 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the BMA6137828 bond issued by Banco Macro S.A., detailing its interest rate and payment schedule. The bond has a current coupon rate of 8.00%, with the next interest payment scheduled for December 23, 2026. The article indicates …

American Express and ALL Accor Expand the Power of Membership with New Global Partnership

HONG KONG, July 23, 2026 /PRNewswire/ -- American Express and ALL Accor, Accor's booking platform and loyalty program, announced a new global partnership rolling out beginning in 2026 across 12 locations, introducing elite status matching and a new Membership Rewards® points transfer option for …

Santacruz Silver Mining (NASDAQ:SCZM) Trading Down 7.7% - What's Next?

American Express (AXP) Expands Accor Rewards And Paymode B2B Partnerships

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. American Express (NYSE:AXP) and Accor's ALL loyalty program have launched a global partnership that introduces points transfer and elite status matching across multiple …

MacroGenics’ MGC026 meets trial threshold in head and neck cancer

MacroGenics Inc. announced that its Phase 1 study for MGC026, an antibody-drug conjugate, met the pre-specified response threshold in the head and neck cancer cohort, allowing it to advance to Stage 2 enrollment. Interim results from the study, which has enrolled 74 patients, will …

BMA6137828 Bond Risk Profile

This article provides a risk profile for the Banco Macro S.A. bond BMA6137828, maturing on June 23, 2029, with an 8.0% coupon. It highlights various metrics for credit risk assessment, including security level, inflation protection, and issuer rating. Additionally, it mentions access to exclusive …

BMA stock trades steady as Banco Macro reports resilient earnings and capital ratios

Banco Macro (NYSE: BMA) has demonstrated resilient earnings and strong capital ratios, attracting investors despite Argentina's volatile macroeconomic conditions. The bank maintains double-digit returns on equity, robust capital adequacy, and a focus on cost efficiency, outperforming many regional peers. However, the valuation of BMA …

More Ways for Canadians to Travel, Earn and Be Rewarded: American Express and ALL Accor Announce Global Partnership

TORONTO, July 22, 2026 /CNW/ -- American Express and ALL Accor, Accor's booking platform and loyalty program, today announced a new partnership that gives eligible Canadian Cardmembers a new way to transfer Membership Rewards® points and access ALL Accor elite status benefits, which will …

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has received an average analyst rating of "Moderate Buy" from five analysts, with a consensus 12-month price target of $11.67. The company's stock was trading at $1.67, with a market cap of approximately $71.5 million, significantly below its 12-month high. …

ACRES Commercial Realty (ACR) Projected to Release Earnings on Wednesday

Acrophyte Hospitality Trust Closes Sale of US Hotel; Shares Up 7%

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Acrivon Therapeutics will present at the AACR D3 Conference, showcasing its AP3 platform for drug discovery and development. The presentations will include mechanistic data on ACR-2316, a WEE1/PKMYT1 inhibitor, highlighting its potent single-agent activity and superior therapeutic index. Early clinical responses for ACR-2316 across …

SZCL0 Stock Price and Chart — BCS:SZCL0

This page provides an overview of Santacruz Silver Mining Ltd. (SZCL0) stock on the Santiago Stock Exchange, including its current trading status, IPO date, and ISIN. The article also features community discussions and trading ideas related to the stock's performance and answers frequently asked …

Acrivon to Present Tumor Shrinkage and Partial Responses at AACR

Acrivon Therapeutics will present Phase 1/2 data for its drug candidate ACR-2316 at the AACR D3 Conference, highlighting its AP3 platform for drug discovery. Early observations for ACR-2316, a WEE1/PKMYT1 inhibitor, show tumor shrinkage, partial responses, and durable clinical benefit in AP3-predicted tumor types, …

Acrow (ASX:ACF) Closes in Positive Territory—Can The Stock Rebuild Long-Term Momentum?

Price to book forward of Santacruz Silver Mining Ltd. – NEO:SCZ

This article provides the "Price to book forward" for Santacruz Silver Mining Ltd. (NEO:SCZ) as offered by TradingView. It indicates that the market is closed, with no trades observed. The data is made available through human processing and is presented in English.

MacroGenics (MGNX): Millennium group discloses 3.7% beneficial stake in amended 13G

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G for MacroGenics (MGNX), disclosing a collective beneficial ownership of 2,374,296 shares, which represents 3.7% of the outstanding common stock. This filing indicates that the reporting persons now …

New Strong Sell Stocks for July 20th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: ACRES Commercial Realty Corp. ACR is a real estate investment trust. The Zacks Consensus Estimate for its current year earnings has been revised 9.8% downward over the last 60 days. …

Maxim Group Maintains Santacruz Silver Mining(SCZM.US) With Buy Rating, Cuts Target Price to $10

Maxim Group has reiterated its Buy rating on Santacruz Silver Mining (SCZM.US) but has lowered its price target for the company to $10. This adjustment reflects an updated valuation while maintaining a positive outlook on the stock's future performance.

Santacruz Silver Mining (NASDAQ:SCZM) Trading Down 0.7% - Time to Sell?

MacroGenics stock gains after FDA priority review as revenue rises and cash runway extends

MacroGenics stock experienced gains following an FDA priority review for vobramitamab duocarmazine and significant revenue increases. The company reported a 31.1% rise in Q1 2024 revenue, totaling $45.7 million, with collaborative and licensing arrangements being the primary driver. This financial performance, coupled with reduced …